Morningstar - Business Wire: Opexa Therapeutics Launches Tovaxin ...
About TERMS. The Tovaxin Phase IIb clinical study
will include 150 patients in a multicenter, randomized
double blind, placebo-controlled trial designed ...

BCM Technologies : News and Events
"In our upcoming double-blind placebo-controlled
Phase IIb clinical trial, named TERMS (Tovaxin
for Early Relapsing Multiple Sclerosis), patients with ...

Opexa Achieves Midpoint in Patient Admissions in Phase IIb Trial ...
MultiCell Establishes Clinical Development Team to Lead UK
Phase IIb ... Use of this site is governed by our Terms of
Use Agreement and Privacy Policy. ...

Multiple Sclerosis Resource Centre : Tovaxin
About TERMS. The Tovaxin Phase IIb clinical study
will include 150 patients in a multicenter, randomised,
double blind, placebo-controlled trial designed ...

Opexa Begins Dosing Patients in Phase IIb Trial of Tovaxin™ for ...
As previously announced, this Phase IIb clinical study will
include 150 ... A total of 100 patients will receive Tovaxin,
while 50 will receive placebo. ...

Biospace.com
Opexa Therapeutics (OPXA) Launches Tovaxin(TM)
Clinical Trial Website For ... its Phase IIb study of
Tovaxin™ (“TERMS” study) located at www.tovaxin.com. ...

RTTNews - Breaking News, financial breaking News, Positive EPS ...
The Tovaxin Phase IIb clinical study is a multicenter,
randomized, ... have been enrolled in the TERMS clinical
trial and the company expects enrollment to ...

Tovaxin - Wikipedia, the free encyclopedia
This multicenter, randomized, double blind, placebo-controlled
Phase IIb clinical study is designed primarily to evaluate
the efficacy, ...

Opexa Therapeutics - Tovaxin™
PHASE IIb The third clinical trial (TERMS Study) will
start in December 2005. ... Information on Opexa Therapeutics
Phase 2b Tovaxin Clinical Trial at ...

Opexa Achieves Midpoint in Patient Admissions in Phase IIb Trial ...
As previously announced, this Phase IIb clinical study will include
150 ... Tovaxin(TM), a T-cell therapy for multiple sclerosis is in
Phase IIb trials. ...